Survival rate

DGAP-News: DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Tuesday, November 30, 2021 - 8:05am

Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.

Key Points: 
  • Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.
  • The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological interest to target cells and increases the intracellular accumulation to these targeted cells.
  • Another infectious disease vaccine in development at Defence Therapeutics is AccuVAC-PT009 targeting HPV.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China

Monday, November 29, 2021 - 1:05pm

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today reported that its partners Alphamab Oncology (stock code: 9966.HK) and 3D Medicines (Beijing) Co., Ltd. announced that envafolimab (KN035), the world's first single-domain PD-L1 antibody formulated for subcutaneous injection received marketing authorization from the Chinese National Medical Products Administration (NMPA).

Key Points: 
  • Envafolimab was well tolerated in this study and no cases of immune-related pneumonitis, immune-related colitis, or immune-related nephritis were reported.
  • In December 2019, Alphamab Oncology, 3D Medicines and TRACON entered into a collaboration whereby TRACON has the right to develop and commercialize envafolimab in soft tissue sarcoma in North America.
  • Four products have advanced into phase I-III clinical trials or pre-marketing stage in China, the United States, Japan and Australia.
  • The world's first subcutaneous injection PD-L1 antibody, envafolimab, is currently under clinical development in the United States, China and Japan.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Monday, November 22, 2021 - 1:40am

"AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.

Key Points: 
  • "AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML."
  • The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Monday, November 22, 2021 - 12:10pm

AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.

Key Points: 
  • AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
  • This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML.
  • The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
  • The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.

STAR 99.1 Partners With PINK Breast Center to Promote Breast Cancer Awareness Month and Inspire Women to Get Mammograms

Friday, November 19, 2021 - 5:25pm

In recognition of Breast Cancer Awareness Month, breast cancer survivors shared their stories with Kristen James of STAR 99.1 to inspire women to advocate for themselves and encourage them to get their annual mammograms.

Key Points: 
  • In recognition of Breast Cancer Awareness Month, breast cancer survivors shared their stories with Kristen James of STAR 99.1 to inspire women to advocate for themselves and encourage them to get their annual mammograms.
  • Ms. James also interviewed Dr. Lisa Sheppard to dispel common myths about breast cancer and educate women about the latest mammography technology.
  • This technology [3D mammo plus Artificial Intelligence] has made a tremendous impact on patient care at PINK Breast Center, according to Lisa Sheppard, MD, founder of PINK Breast Center.
  • Because there is a 99% survival rate for women with breast cancer when it is detected early, STAR 99.1 and PINK Breast Center partnered to urge women to learn about all their options and be vigilant about their health.

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

Friday, November 19, 2021 - 12:42pm

The results reported today are from the final challenge timepoint in a preclinical study evaluating the efficacy of ATI-1701 28 days, 90 days, and one year after vaccination.

Key Points: 
  • The results reported today are from the final challenge timepoint in a preclinical study evaluating the efficacy of ATI-1701 28 days, 90 days, and one year after vaccination.
  • At each challenge timepoint, cohorts of vaccinated and unvaccinated animals received a lethal exposure of aerosolized Francisella tularensis, the causative agent of tularemia.
  • In January 2020, Appili had reported 90-day efficacy results, with 100% of ATI-1701 vaccinated animals surviving exposure compared to 0% of the controls.
  • Both 28- and 90-day efficacy data have also been presented previously by Appilis partners MRIGlobal at biodefense conferences in the U.S.

illumigyn™ Partners with Peramare Enterprises Ltd. and Supported by Afreximbank to Deploy Its Cutting-Edge Gynecological Imaging System and Cloud-Based Platform throughout Africa

Monday, November 22, 2021 - 9:00am

DURBAN, South Africa, Nov. 22, 2021 /PRNewswire/ -- illumigyn , the world's first remote gynecological imaging platform, announced today that it signed a new distribution agreement with Peramare Enterprises to deploy 20,000 Gynescopes systems across Africa.

Key Points: 
  • DURBAN, South Africa, Nov. 22, 2021 /PRNewswire/ -- illumigyn , the world's first remote gynecological imaging platform, announced today that it signed a new distribution agreement with Peramare Enterprises to deploy 20,000 Gynescopes systems across Africa.
  • Cervical cancer is also the second most common and fatal cancer in women in Sub-Saharan Africa (SSA); more women die of cervical cancer each year than during childbirth.
  • Yet, in a recent 11-country study, the survival rate from cervical cancer in Sub-Saharan Africa is 33% five years post-diagnosis.
  • "Cervical cancer is among the highest killers of our women," said Mrs. Oluranti Doherty, Director of Export Development of Afreximbank.

illumigyn™ Partners with Peramare Enterprises Ltd. and Supported by Afreximbank to Deploy Its Cutting-Edge Gynecological Imaging System and Cloud-Based Platform throughout Africa

Monday, November 22, 2021 - 9:01am

DURBAN, South Africa, Nov. 22, 2021 /PRNewswire/ -- illumigyn, the world's first remote gynecological imaging platform, announced today that it signed a new distribution agreement with Peramare Enterprises to deploy 20,000 Gynescopes™ systems across Africa. This milestone propels illumigyn's commitment to combat the prevalent and high mortality rates of cervical cancer in Africa by providing women with accessible screenings and remote-diagnostics platforms.

Key Points: 
  • DURBAN, South Africa, Nov. 22, 2021 /PRNewswire/ -- illumigyn , the world's first remote gynecological imaging platform, announced today that it signed a new distribution agreement with Peramare Enterprises to deploy 20,000 Gynescopes systems across Africa.
  • Cervical cancer is also the second most common and fatal cancer in women in Sub-Saharan Africa (SSA); more women die of cervical cancer each year than during childbirth.
  • Yet, in a recent 11-country study, the survival rate from cervical cancer in Sub-Saharan Africa is 33% five years post-diagnosis.
  • "Cervical cancer is among the highest killers of our women," said Mrs. Oluranti Doherty, Director of Export Development of Afreximbank.

New Report: Lung Cancer Survival Has Increased, but Remains Significantly Lower for People of Color

Tuesday, November 16, 2021 - 5:01am

CHICAGO, Nov. 16, 2021 /PRNewswire/ --The new "State of Lung Cancer" report reveals that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.

Key Points: 
  • CHICAGO, Nov. 16, 2021 /PRNewswire/ --The new "State of Lung Cancer" report reveals that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.
  • "The report highlights important news more people are surviving lung cancer; however, it also underscores the fact that, sadly, health disparities persist for communities of color.
  • In fact, while the national lung cancer survival rate increased to 23.7%, it remains at only 20% for communities of color and 18% for Black Americans.
  • Lung Cancer Screening:Lung cancer screening with annual low-dose CT scansfor those at high riskcan reduce the lung cancer death rate by up to 20%.

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797

Friday, November 12, 2021 - 12:00pm

Importantly, little has changed in respiratory failure management since 20001 so the use of iNKT therapies in critical care medicine could potentially be a game changer.

Key Points: 
  • Importantly, little has changed in respiratory failure management since 20001 so the use of iNKT therapies in critical care medicine could potentially be a game changer.
  • Collectively, our SITC data highlight the disease modifying potential of agenT-797 in cancer and infections, said Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics.
  • AgenT-797 in COVID-19 respiratory failure showed a 77% survival rate in older, ventilated patients compared to the national average approximating 20-30%.
  • AgenT-797 demonstrated early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma without lymphodepletion.